Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer

Cancer Chemother Pharmacol. 1990;27(2):101-5. doi: 10.1007/BF00689091.

Abstract

In this study the influence of amino-glutethimide (AG) on the disposition of medroxyprogesterone acetate (MPA) and megestrol acetate (MA) was studied. When 1,000 mg AG daily was supplementally given to six patients on chronic treatment with MPA (1,000 mg/day) or MA (160 mg/day), mean serum levels of progestin were reduced by 74% as compared with control levels (P less than 0.03). AG did not change the blood clearance rate of MPA when the latter was given i.v. This discrepancy between AG's influence on oral and parenteral progestin disposition could be explained by pharmacokinetic properties of the progestins, and our results suggest that AG stimulates the metabolism of progestins. The decrease in MPA and MA serum levels was accompanied by an increase in serum cortisol, sex hormone-binding globulin (SHBG) and testosterone levels. This suggests that AG reduces the biological activity of progestins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Aged
  • Aminoglutethimide / pharmacology*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / metabolism*
  • Drug Interactions
  • Female
  • Humans
  • Injections, Intravenous
  • Medroxyprogesterone / blood
  • Medroxyprogesterone / pharmacokinetics*
  • Medroxyprogesterone / therapeutic use
  • Megestrol / analogs & derivatives*
  • Megestrol / blood
  • Megestrol / pharmacokinetics
  • Megestrol / therapeutic use
  • Megestrol Acetate
  • Menopause*
  • Middle Aged
  • Progestins / blood

Substances

  • Progestins
  • Aminoglutethimide
  • Megestrol
  • Medroxyprogesterone
  • Megestrol Acetate